Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany.
GENYO. Centre for Genomics and Oncological Research, Pfizer / University of Granada / Andalusian Regional Government, Granada, Andalusia, Spain.
Best Pract Res Clin Rheumatol. 2023 Dec;37(4):101949. doi: 10.1016/j.berh.2024.101949. Epub 2024 May 10.
SLE is a highly variable systemic autoimmune disease. Its immunopathological effector phase is partly understood. However, the background of its variability is not. SLE classification criteria have been relying on the clinical manifestations and standard autoimmune serology. This still holds true for the 2019 EULAR/ACR classification criteria. On one hand, this has led to significant precision in defining patients with SLE. On the other hand, the information in the criteria neither helps understanding the individual patient's pathophysiology, nor does it predict the efficacy of the available immunomodulatory therapies. Chances of further improvement of clinical criteria are most likely limited. This is where new multi-omic approaches have started to make an impact. While not yet able to differentiate diseases with the same precision as the classification criteria, the results of these studies go far beyond the scope of the criteria with regard to immune dysregulation. Looking at both sides in detail, we here try to synthesize the available data, aiming at a better understanding of SLE and its immune pathophysiology.
SLE 是一种高度可变的系统性自身免疫性疾病。其免疫病理效应阶段的部分机制已被阐明。然而,其变异性的背景仍不清楚。SLE 的分类标准一直依赖于临床表现和标准自身抗体检测。这在 2019 年 EULAR/ACR 分类标准中仍然适用。一方面,这使得定义 SLE 患者的方法具有显著的准确性。另一方面,标准中的信息既不能帮助理解个体患者的病理生理学,也不能预测现有免疫调节治疗的疗效。进一步改善临床标准的机会很可能受到限制。这就是新的多组学方法开始产生影响的地方。虽然这些方法还不能像分类标准那样精确地区分疾病,但与标准相比,这些研究的结果在免疫失调方面远远超出了标准的范围。详细研究这两个方面,我们试图在这里综合现有数据,旨在更好地理解 SLE 及其免疫病理生理学。